Mild cognitive impairment: the Manchester consensus

Validation of an algorithm for detecting turning in people with cognitive impairment, considering dementia disease subtype

BACKGROUND

Turning manoeuvres are an essential component of mobility and are vital for effective real-world navigation. Turning is more challenging than straight-line walking, involving complex cognitive functions to execute multi-segment co-ordination. Therefore, people with cognitive impairment (PwCI) may be more susceptible to impaired turning performance. Inertial measurement units (IMUs) can be used to quantify turning performance; however, IMU-based algorithms have not yet been validated for PwCI, or across dementia disease subtypes.

RESEARCH QUESTION

Is a custom-built algorithm for accurately detecting turn start and end valid for use in PwCI and in different dementia disease subtypes?

METHODS

Sixty-six PwCI due to Alzheimer's disease, Lewy body disease and vascular dementia, along with 23 cognitively healthy older adults (controls) were included. Participants wore an IMU on their lower back while completing six 10-m intermittent walks, segmented by 180° turns. A 2D colour video camera was used as the reference system. Videos were reviewed by two independent blinded raters annotating turn start and end. Agreement (intra-class correlation (ICC (2,1)), Spearman's rho and Limits of agreement) and error (Root mean square error; RMSE and bias) between the raters (rater 1 vs. 2) and the algorithm (rater vs. algorithm) were evaluated.

RESULTS

There was excellent agreement (rater-rater and rater-algorithm) for detecting turn start and end for PwCI and across dementia disease subtypes (rho = 1.00, ICC = 1.00). The error between raters was lower (RMSE < 0.72 s, bias < 0.41 s) than the error between raters and algorithm (RMSE < 1.29 s, bias < 1.4 s). Error was lowest for controls (RMSE < 0.94 s), followed by AD (RMSE < 1.21 s) and LBD (RMSE < 1.29 s).

SIGNIFICANCE

Key findings suggest that this algorithm can detect turn start and end using an IMU in PwCI in agreement with a reference system (video ratings). Future research should consider the clinical application of turning assessment in PwCI, such as its ability to differentiate dementia disease subtypes to support accurate diagnosis.

Factors associated with cognitive impairment for people with mental health disorders: screening from general hospitals and an emergency care unit in Brazil

BACKGROUND

Emergency services and mental health units in general hospitals play a central role in the initial care and treatment of individuals with mental disorders. Early diagnosis and treatment of mental disorders and substance abuse can reduce cognitive deficits in this population. This study aims to investigate the factors associated with cognitive impairment for people with mental health disorders and addictions.

METHODS

This is a cross-sectional study performed in two general hospitals and an Emergency Care Unit (UPA) in cities in the metropolitan region of Porto Alegre, Rio Grande do Sul, Brazil. The interRAI Emergency Screener for Psychiatry (ESP) was used to describe the study population and to build an adjusted logistic model for the risk factors of cognitive impairment.

RESULTS

A total of 324 persons participated in the study (mean age: 41.8 ± 14.27, 50,2% female). The profile of people admitted to the different locations varied in several aspects according to the interRAI scales. The UPA received patients with acute conditions and higher scores on the Aggressive Behavior Scale, Mania Scale, the Scale of Harm to Others, and the Scale of Positive Symptoms. Patients at the university hospital had the highest rates of social withdrawal and a higher proportion of individuals with no insight into their mental health problems. The factors with the highest odds ratio were a diagnosis of schizophrenia (O.R.: 3.07; C.I. 1.13; 8.32), followed by self-care inability (O.R.: 2.87, 1.43; 5.77) and the aggressive behavior scale (2.85, 1.10; 7.44). A history of discharges, the Mania Scale and sleeping problems were also significantly associated with cognitive impairment. People being admitted to the UPA had lower odds of having cognitive impairment (O.R.: 0.18; 0.07; 0.45).

CONCLUSION

People diagnosed with schizophrenia were at very high risk of cognitive impairment. A prior history of discharges, inability to self-care, aggressive behavior, symptoms of mania and sleeping disturbances were also identified as risk factors. The interRAI EPS instrument showed to be useful to identify people with mental health disorders and substance abuse who were at risk of cognitive impairment. By early detecting these clients, professionals can refer them to adequate treatment, before symptoms increase.

Ensemble network using oblique coronal MRI for Alzheimer's disease diagnosis

Alzheimer's disease (AD) is a primary degenerative brain disorder commonly found in the elderly, Mild cognitive impairment (MCI) can be considered a transitional stage from normal aging to Alzheimer's disease. Therefore, distinguishing between normal aging and disease-induced neurofunctional impairments is crucial in clinical treatment. Although deep learning methods have been widely applied in Alzheimer's diagnosis, the varying data formats used by different methods limited their clinical applicability. In this study, based on the ADNI dataset and previous clinical diagnostic experience, we propose a method using oblique coronal MRI to assist in diagnosis. We developed an algorithm to extract oblique coronal slices from 3D MRI data and used these slices to train classification networks. To achieve subject-wise classification based on 2D slices, rather than image-wise classification, we employed ensemble learning methods. This approach fused classification results from different modality images or different positions of the same modality images, constructing a more reliable ensemble classification model. The experiments introduced various decision fusion and feature fusion schemes, demonstrating the potential of oblique coronal MRI slices in assisting diagnosis. Notably, the weighted voting from decision fusion strategy trained on oblique coronal slices achieved accuracy rates of 97.5% for CN vs. AD, 100% for CN vs. MCI, and 94.83% for MCI vs. AD across the three classification tasks.

Impact of dual sensory impairment on cognition in older Chinese adults: a moderated chain-mediated effect

Objective

Although sensory impairment has been identified as a risk factor for cognitive decline, little is known about the underlying mechanisms that connect dual sensory impairment to cognitive ability. This research used a moderated chain-mediated model to investigate the underlying mechanisms behind the association between dual sensory impairment and cognitive ability.

Methods

People aged 60 years and older from seven medical institutions, three communities, and five nursing homes in Zunyi city, Guizhou Province, were selected for the study from October 2022 to September 2023 via convenience sampling. Data on demographic characteristics, self-reported hearing and vision loss, and Self-Rating Anxiety Scale (SAS), 15-item Geriatric Depression Scale (GAD-15), Frailty Scale (FRAIL), and Mini-Mental State Examination (MMSE) scores were collected. A moderated chain mediator was used to analyze the underlying mechanisms and pathways of the relationships among anxiety, depression, and cognitive ability in individuals with dual sensory impairment, as well as the moderating role of frailty in this connection.

Results

A total of 7,021 older adults were included, 3,598 (51.25%) of whom were male, with a mean age of 72.01 ± 7.17 years. Dual sensory impairment had a significant direct effect on cognitive ability, with an effect size of -3.134, followed by anxiety and depression, which not only independently mediated the relationship between dual sensory impairment and cognitive ability but also jointly had a chain mediation effect, with mediation effect sizes of -0.766 and -0.182, respectively, and a chain mediation effect size of -0.257. In addition, the interaction effect of dual sensory impairment and frailty was significantly predictive of cognitive ability (effect value = -0.575, p < 0.001).

Conclusion

The mechanisms of action between dual sensory impairment, anxiety, depression, cognitive performance, and frailty are shown in this study. This finding also implies that therapies for psychological issues, frailty, and sensory functioning in older adults can preserve their cognitive ability.

"Chew on This: Oral health is associated with cognitive function among Canadians enrolled in the Canadian Longitudinal Study on Aging"

OBJECTIVES

Life expectancy has increased globally, leading to a higher proportion of older adults, particularly in developed countries like Canada. This demographic shift strains healthcare systems and is associated with an increased risk of dementia, a condition characterised by cognitive decline. Oral health has emerged as a potential modifiable risk factor for dementia, yet the evidence remains conflicting. This study examines the association between oral health parameters and cognitive functioning in the Canadian population, utilizing data from the Canadian Longitudinal Study on Aging (CLSA).

METHODS

A cross-sectional analysis was conducted using baseline data from the comprehensive cohort of the CLSA, comprising 30,097 participants aged 45-85 years. Oral health was assessed via self-reported oral health (SROH) and masticatory ability (MA). Cognitive function was evaluated using a battery of neuropsychological tests, and a Cognitive Impairment Indicator (CII) was derived. Logistic regression models were employed to examine the association between oral health and cognitive impairment, adjusting for confounders.

RESULTS

We found that poor SROH was not significantly associated with cognitive impairment (OR = 1.19, 95 % CI = 0.63-2.09), while inadequate MA was significantly associated with higher odds of cognitive impairment (OR = 2.82, 95 % CI = 1.82-4.25).

CONCLUSION

The findings suggest a significant association between perceived MA and cognitive impairment within this cohort.. These results suggest that perceived ability to chew could be a potentially modifiable risk factor for cognitive decline. Further research is warranted to explore the mechanisms underlying these associations and to develop targeted preventive strategies.

CLINICAL SIGNIFICANCE

This paper highlights that middle aged and elderly Canadians with inadequate MA have a 2.82 times higher odds of experiencing cognitive impairment. Addressing chewing difficulties may serve as a modifiable risk factor for early cognitive decline, offering a potential window of opportunity to slow down the process of cognitive decline among aging populations.

Effects of Tai Chi Chuan on cognitive function in adults 60 years or older with mild cognitive impairment: a systematic review and meta-analysis

Background

Mild cognitive impairment (MCI) is an intermediate stage between normal aging and dementia. Emerging evidence has demonstrated that mind-body interventions may enhance cognitive function. To elucidate whether stand-alone Tai Chi Chuan (TCC) intervention confers domain-specific benefits on executive function, memory, and global cognition, further investigations should be conducted.

Purpose

This systematic review and meta-analysis of randomized controlled trials (RCTs) examined TCC's effects on global cognition, memory, and executive function, and its duration-response relationship in adults 60 years or older with MCI.

Methods

Seven electronic databases were searched for relevant literature, with English as the sole inclusion criterion for language. The methodological quality and risk of bias for all included RCTs were assessed using the Cochrane Risk of Bias (2.0) tool. The pooled effect sizes were evaluated using standardized mean differences (SMD) and 95% confidence intervals (CI). A p-value <0.05 was considered statistically significant.

Results

Nine of the 1,442 publications met the inclusion criteria, comprising RCTs involving 1,066 participants (68.95% female) with a mean age of 74.1 (±7.4) years. Long-term TCC demonstrated significant effects on global cognition (p < 0.001; SMD = 0.488; 95% CI: 0.222-0.754), whereas short-term TCC did not (p = 0.172; SMD = 0.682; 95% CI: -0.397-1.660). Overall, TCC showed significant global cognitive benefits (p = 0.003; SMD = 0.526; 95% CI: 0.184-0.869). Long-term memory showed no improvement (p = 0.214; SMD = 0.162; 95% CI: -0.094-0.417), while short-term memory improved significantly (p = 0.021; SMD = 1.010; 95% CI: 0.155-1.865). The overall effect of TCC on memory was significant (p = 0.005; SMD = 0.580; 95% CI: 0.178-0.982). Both short-term and long-term improvements in executive function were significant (p = 0.006; SMD = -0.791; 95% CI: -1.353 to -0.230).

Conclusion

The study confirmed TCC's duration-dependent effects on global cognition in older adults (≥60 years) with MCI. Memory exhibited nonlinear temporal dynamics, characterized by short-term acceleration and long-term plateau, while executive function demonstrated temporal invariance with comparable efficacy across intervention durations.

Systematic Review Registration

https://www.crd.york.ac.uk/PROSPERO/home, identifier CRD42024587754.

Cultural variation in trust and acceptability of artificial intelligence diagnostics for dementia

Digital health innovations hold diagnostic and therapeutic promise but may be subject to biases for underrepresented groups. We explored perceptions of using artificial intelligence (AI) diagnostics for dementia through a focus group as part of the Automated Brain Image Analysis for Timely and Equitable Dementia Diagnosis (ABATED) study. Qualitative feedback from a diverse public engagement group indicated that cultural variations in trust and acceptability of AI diagnostics may be an unrecognised source of real-world inequity. Efforts focused on the adoption of AI diagnostics in memory clinic pathways should aim to recognise and account for this issue.

Diagnostic journey and management of patients with mild cognitive impairment and Alzheimer's disease dementia: A multinational, real-world survey

BackgroundAn Alzheimer's disease (AD) diagnosis made in the earliest symptomatic stages substantially benefits patients and their care partners. However, little is known regarding the clinical, healthcare system-level, and patient-specific barriers that hinder timely diagnosis and treatment.ObjectiveTo explore real-world practices surrounding the diagnostic journey and management of mild cognitive impairment (MCI)/AD dementia patients.MethodsData were drawn from Adelphi Real World Dementia Disease Specific Programme™, a cross-sectional survey of physicians treating MCI/AD dementia patients in France, Germany, Italy, Spain, the United Kingdom, the United States, and Japan between 2022 and 2024.ResultsOverall, 779 physicians reported data on 5551 patients. Physicians indicated current disease severity for 5421 patients; 37.2% had MCI (87.3% with suspected prodromal AD and 12.7% undetermined etiology), 17.2% AD with mild dementia, 31.1% AD with moderate dementia, and 14.5% AD with severe dementia. When not immediately diagnosed, the median time from first consultation to initial diagnosis was 8.9 and 12.6 weeks when patients first consulted and were diagnosed by either a primary care practitioner (PCP) or a specialist, respectively, compared with 21.6 weeks when a PCP referred to a specialist for diagnosis. Diagnostic delays were predominantly due to specialist wait times. Few patients had diagnostic AD biomarker tests (cerebrospinal fluid testing 9.5%, amyloid positron emission tomography 3.7%, AD-blood tests 5.3%).ConclusionsTimely MCI and AD diagnosis is impeded by referral delays and limited use of biomarker testing. Addressing these critical care gaps requires enhanced physician training, reduced wait times and increased biomarker utilization for early management.

Effects of dyadic psychosocial education on people with mild cognitive impairment or dementia and their informal caregivers: protocol for a systematic review and meta-analysis

INTRODUCTION

Mild cognitive impairment (MCI) and dementia impose a significant burden on individuals and their caregivers. Dyadic psychosocial education, which treats care recipients and their caregivers as a pair of active participants, has the potential to improve health outcomes for people with cognitive impairment and their caregivers. However, the results of recent studies on this subject are contradictory. We aim to evaluate the effectiveness of dyadic psychosocial education for people with MCI or dementia and their informal caregivers.

METHODS AND ANALYSIS

Six databases will be searched. We will include all randomised controlled trials that compare dyadic psychosocial education to usual care. The risk of bias will be assessed using the Cochrane Risk-of-Bias Assessment Tool (V.2). Meta-analyses, subgroup analyses and sensitivity analyses will be performed using Stata V.15.1. A narrative synthesis will be conducted if quantitative analysis is not feasible.

ETHICS AND DISSEMINATION

This study and subsequent systematic review will not collect individual-level data and, therefore, do not require ethics committee approval. Peer-reviewed publications will disseminate the study results.

PROSPERO REGISTRATION NUMBER

CRD42024497554.

Mild cognitive impairment in amyotrophic lateral sclerosis: current view

Amyotrophic lateral sclerosis (ALS) is a fatal multi-system neurodegenerative disorder with no effective treatment or cure. Although primarily characterized by motor degeneration, cognitive dysfunction is an important non-motor symptom that has a negative impact on patient and caregiver burden. Mild cognitive deficits are present in a subgroup of non-demented patients with ALS, often preceding motor symptoms. Detailed neuropsychological assessments reveal deficits in a variety of cognitive domains, including those of verbal fluency and retrieval, language, executive function, attention and verbal memory. Mild cognitive impairment (MCI), a risk factor for developing dementia, affects between 10% and over 50% of ALS patients. Neuroimaging revealed atrophy of frontal and temporal cortices, disordered white matter Integrity, volume reduction in amygdala and thalamus, hypometabolism in the frontal and superior temporal gyrus and anterior insula. Neuronal loss in non-motor brain areas, associated with TDP-43 deposition, one of the morphological hallmarks of ALS, is linked to functional disruption of frontostriatal and frontotemporo-limbic connectivities as markers for cognitive deficits in ALS, the pathogenesis of which is still poorly understood. Early diagnosis by increased cerebrospinal fluid or serum levels of neurofilament light/heavy chain or glial fibrillary acidic protein awaits confirmation for MCI in ALS. These fluid biomarkers and early detection of brain connectivity signatures before structural changes will be helpful not only in establishing early premature diagnosis but also in clarifying the pathophysiological mechanisms of MCI in ALS, which might serve as novel targets for prohibition/delay and future adequate treatment of this debilitating disorder.

The use of outpatient support services: Differences between people with mild cognitive impairment and people with mild to moderate dementia

BackgroundLittle is known about the utilization of outpatient support services by people with mild cognitive impairment (MCI).ObjectiveThis study aimed to analyze the use of support services by people with MCI compared to people with mild to moderate dementia.MethodsThe data basis is the multicenter, prospective register study 'Digital Dementia Register Bavaria - digiDEM Bayern'. The sample consists of 913 people with cognitive impairment, including 389 with MCI and 524 with mild to moderate dementia. Classification into 'MCI' and 'mild to moderate dementia' is based on the Mini-Mental State Examination and Montreal Cognitive Assessment. The use of support services was surveyed using the Dementia Assessment of Service Needs. Fisher's exact test and multiple linear regression were conducted to analyze for group differences.ResultsFour out of thirteen support services are used less frequently by people with MCI than by people with mild to moderate dementia: 'Outpatient care' (p < 0.001, φ = -0.199), 'Acquisition of aids' (p = 0.004, φ = -0.096), 'Adult daycare' (p < 0.001, φ = -0.290), and 'Respite care' (p = 0.029, φ = -0.095). Even the overall utilization rate is lower for people with MCI (b = -0.18, p = 0.027), although other factors such as a care level (b = 1.01, p < 0.001) are more strongly related.ConclusionsThere are differences in utilization between people with MCI and people with mild to moderate dementia, but these are small. Therefore, access to support services should be provided at the first signs of cognitive impairment.

Developing a core outcome set for interventions in people with mild cognitive impairment: study protocol

INTRODUCTION

There is no standardised national guidance on clinical management for people living with mild cognitive impairment (MCI), and therapeutic interventions are limited. Understanding what outcomes are important and meaningful to people living with MCI and developing a core outcome set (COS) for research and clinical practice will improve the impact of clinical research and contribute towards developing effective care pathways for MCI. This study aims to develop a COS for adults living with MCI intended for use in interventional and clinical settings.

METHODS AND ANALYSIS

The COS will be developed using a five-stage study design: (1) systematic literature search, (2) qualitative interviews, (3) evidence synthesis from stages 1 and 2, (4) two-round Delphi survey and (5) consensus meeting(s). First, we will conduct an umbrella review of existing MCI interventional studies and extract a list of outcomes. Qualitative interviews will be held with key stakeholders including individuals living with MCI, friends and family, and relevant professionals to identify further outcomes considered important. Outcomes from the review and interviews will be synthesised into a 'long list' of outcomes for potential inclusion in the COS. Two rounds of Delphi surveys followed by a consensus meeting will be used to reach stakeholder consensus on which outcomes should be included in the final COS.

ETHICS AND DISSEMINATION

We have received ethical approval from the London-Queen Square Research Ethics Committee (23/PR/1580). Patient and public involvement and engagement are central to developing the COS. The results will be disseminated via conferences, peer-reviewed publications, briefing notes to key agencies, to the public via social media and blog posts and directly to stakeholders who participate in the project.

TRIAL REGISTRATION NUMBER

Core Outcome Measures in Effectiveness Trials Initiative 2117; PROSPERO registration: CRD42023452514.

Effectively capturing memory deficits: New advances in the use of the In-out-Test for cognitive Test post-stroke

OBJECTIVE

This study evaluated the reliability and validity of the In-Out-Test for detecting episodic memory deficits in stroke patients and explored its potential as a clinical test.

METHODS

A total of 75 stroke patients and 120 healthy controls underwent tests, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Picture-Based Memory Impairment Screen (PMIS), and In-Out-Test. Reliability metrics (Cronbach's α, inter-scorer reliability, test-retest reliability), criterion validity, corrected item-total correlation, hierarchical regression analysis and ROC curve analysis were performed to determine the sensitivity and specificity of the In-Out-Test.

RESULTS

Stroke patients scored lower across all tests (p < 0.001), with the largest difference in the In-Out-Test (d = 0.99). The In-Out-Test correlated strongly with other cognitive tests (r = 0.79-0.85 in stroke patients; r = 0.66-0.78 in controls). It explained an additional 4.5% of variance in MoCA-MIS scores (p < 0.001). Reliability was high (Cronbach's α = 0.835; inter-rater ICCs = 0.911-0.925; test-retest ICCs = 0.764-0.802). ROC analysis showed an AUC of 0.747, with a sensitivity of 0.708 and specificity of 0.680 at a cutoff of 10.5.

CONCLUSION

Preliminary findings indicated that the In-Out-Test showed potential in detecting episodic memory impairments in stroke patients, warranting further validation in larger cohorts.

MicroRNAs signatures as potential molecular markers in mild cognitive impairment: a meta-analysis

Mild cognitive impairment (MCI) is characterized by a decline in cognitive functioning without significant interference in daily activities. Its high heterogeneity and elevated conversion rate to dementia pose challenges for accurate diagnosis and monitoring, highlighting the urgent need to identify methodologies focused on the early detection and intervention of MCI. Due to their biological characteristics, microRNAs (miRNAs) are potential candidates as non-invasive molecular markers for the identification and assessment of MCI progression. Therefore, in this study, we conducted a meta-analysis to identify the miRNAs commonly deregulated in MCI, focusing on expression profiles in plasma, serum, and extracellular vesicle samples. Our analysis identified eight upregulated miRNAs, including hsa-miR-149-3p, and four downregulated miRNAs, such as Let-7f-5p. Notably, hsa-miR-149-3p emerged as a central node in interaction networks, suggesting its crucial role in regulating cellular processes relevant to MCI. Additionally, pathway analysis revealed significant enrichment in biological processes associated with transcriptional regulation and neurodegeneration. Our results underscore the potential of circulating miRNAs as non-invasive molecular markers for MCI and open the possibility for new methodologies that enable more accurate diagnosis and monitoring of disease progression. Validating the expression of miRNAs such as hsa-miR-149-3p and Let-7f-5p, along with identifying their functional role in the specific context of MCI, is essential to establish their biological relevance. This work contributes to the understanding of the miRNA profile in mild cognitive impairment using easily accessible samples, which could be useful for the development of various strategies aimed at preventing or delaying MCI in individuals at risk of developing dementia, including Alzheimer's disease.

Effects of Yoga-Like Exercises on Mild and Moderate Alzheimer Disease: A Randomized Controlled Trial Protocol

BACKGROUND

While aerobic exercises have demonstrated efficacy in slowing cognitive decline and improving psychological symptoms associated with cognitive impairments, they may not be feasible due to multiple disabilities. Other gentle exercises with mindful approaches, such as "Yoga-like", have been explored but lack clear evidence.

AIM

To assess the efficacy of a "Yoga-like" intervention on cognitive and psychological features in patients with mild to moderate Alzheimer Disease (AD).

METHODS

We propose a randomized controlled trial design. Patients with mild to moderate AD who are able to undergo neurocognitive assessment and do not have conditions contraindicating deep breathing or extreme postures will be randomly assigned to an intervention group (IG: Yoga-like) or a control group (CG: no intervention). The 'Yoga-like' intervention consists of 30 minutes of exercises combining breathing, postures, concentration, and meditation, conducted three times a week over eight weeks. Both groups will undergo neuropsychological tests at baseline and after eight weeks, including attention, problem-solving, visuospatial abilities, mood and neuropsychiatric symptoms.

EXPECTED RESULTS

It is anticipated that the breathing, concentration, and meditation components of the intervention will improve attention, problem-solving abilities and behavioral symptoms. The postural components are expected to enhance visuospatial control and balance.

TRIAL REGISTRATION

PACTR202407721329710 (https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=30602).

Comparing the predictive validity of four MCI definitions for incident dementia in demographically diverse community-dwelling individuals: Results from the Einstein Aging Study (EAS)

OBJECTIVE

Research examining (MCI) criteria in diverse and/or health-disparate populations is limited. There is a critical need to investigate the predictive validity for incident dementia of widely used MCI definitions in diverse populations.

METHOD

Eligible participants were non-Hispanic White or Black Bronx community residents, free of dementia at enrollment, with at least one annual follow-up visit after baseline. Participants completed annual neurological and neuropsychological evaluations to determine cognitive status. Dementia was defined based on DSM-IV criteria using case conferences. Cox proportional hazard models assessed predictive validity for incident dementia of four specific MCI definitions (Petersen, Jak/Bondi, number of impaired tests, Global Clinical Ratings) at baseline, controlling for age, sex, education, and race/ethnicity. Time-dependent sensitivity and specificity at 2-7 years for each definition, and Youden's index were calculated as accuracy measures.

RESULTS

Participants (N = 1073) ranged in age from 70 to 100 (mean = 78.4 ± 5.3) years at baseline. The sample was 62.5% female, and educational achievement averaged 13.9 ± 3.5 years. Most participants identified as White (70.0%), though Black participants were well-represented (30.0%). In general, MCI definitions differed in sensitivity and specificity for incident dementia. However, there were no significant differences in Youden's index for any definition, across all years of follow-up.

CONCLUSIONS

This work provides an important step toward improving the generalizability of the MCI diagnosis to underrepresented/health-disparate populations. While our findings suggest the studied MCI classifications are comparable, researchers and clinicians may choose to consider one method over another depending on the rationale for evaluation or question of interest.

Specialist clinical pathways in audiology services for adults living with coexisting hearing loss and dementia: a scoping review protocol

INTRODUCTION

Both hearing loss and dementia are associated with ageing, and it is thought that many individuals living with dementia also live with hearing loss. Despite the large comorbidity between these two disorders, there remains a clear lack of established guidelines in audiological services for assessing and managing patients living with dementia. This scoping review aims to examine whether specialist clinical pathways exist in audiology services for people living with coexisting hearing loss and dementia and to describe the specific components and features of these pathways. This review will provide up-to-date information on clinical practice, identifying any gaps in care and in the literature to inform future research hypotheses and best practice guidelines.

METHODS AND ANALYSIS

The methods are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. The following electronic databases will be searched: CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, Scopus and Web of Science. The eligibility criteria are defined according to the domains of the SPIDER (Sample, Phenomenon of Interest, Design, Evaluation and Research type) search strategy tool. Primary research studies and select grey literature sources (eg, practice guidelines) will be eligible if published within the last 15 years. Studies eligible for inclusion must contain adults living with suspected or confirmed dementia, their carers, or clinicians within audiology services. Initial searches were performed on 31 January 2024 and will be updated before completion and submission of the review. Article quality will be appraised using an established tool: the Mixed Methods Appraisal Tool. The results will be synthesised and reported in line with reflexive thematic analysis guidelines.

ETHICS AND DISSEMINATION

No ethical issues are foreseen as the review will collect secondary data only. Findings will be reported by peer-reviewed publication and by national and international academic conferences.

The SLaM Brain Health Clinic: remote biomarker enhanced memory clinic for people with mild cognitive impairment within a National Health Service mental health trust

BACKGROUND

The novel South London and Maudsley Brain Health Clinic (SLaM BHC) leverages advances in remote consultations and biomarkers to provide a timely, cost-efficient and accurate diagnosis in mild cognitive impairment (MCI).

AIMS

To describe the organisation, patient cohort and acceptability of the remote diagnostic and interventional procedures.

METHOD

We describe the recruitment, consultation set-up, the clinical and biomarker programme, and the two online group interventions for cognitive wellbeing and lifestyle change. We evaluate the acceptability of the remote consultations, lumbar puncture, saliva genotyping, and remote cognitive and functional assessments.

RESULTS

We present the results of the first 68 (mean age 73, 55% female, 43% minoritised ethnicity) of 146 people who enrolled for full remote clinical, cognitive, genetic, cerebrospinal fluid and neuroimaging phenotyping. A total of 86% were very satisfied/satisfied with the remote service. In all, 67% consented to lumbar puncture, and 95% of those were very satisfied, all having no significant complications. A total of 93% found taking saliva genotyping very easy/easy, and 93% found the cognitive assessments instructions clear. In all, 98% were satisfied with the Cognitive Wellbeing Group, and 90% of goals were achieved in the Lifestyle Intervention Group.

CONCLUSIONS

The SLaM BHC provides a highly acceptable and safe clinical model for remote assessments and lumbar punctures in a representative, ethnically diverse population. This allows early and accurate diagnosis of Alzheimer's disease, differentiation from other MCI causes and targets modifiable risk factors. This is crucial for future disease modification, ensuring equitable access to research, and provides precise, timely and cost-efficient diagnoses in UK mental health services.

Automated Volumetric Software in Dementia: Help or Hindrance to the Neuroradiologist?

BACKGROUND AND PURPOSE

Brain atrophy occurs in the late stage of dementia, yet structural MRI is widely used in the work-up. Atrophy patterns can suggest a diagnosis of Alzheimer disease (AD) or frontotemporal dementia (FTD) but are difficult to assess visually. We hypothesized that the availability of a quantitative volumetric brain MRI report would increase neuroradiologists' accuracy in diagnosing AD, FTD, or healthy controls compared with visual assessment.

MATERIALS AND METHODS

Twenty-two patients with AD, 17 with FTD, and 21 cognitively healthy patients were identified from the electronic health systems record and a behavioral neurology clinic. Four neuroradiologists evaluated T1-weighted anatomic MRI studies with and without a volumetric report. Outcome measures were the proportion of correct diagnoses of neurodegenerative disease versus normal aging ("rough accuracy") and AD versus FTD ("exact accuracy"). Generalized linear mixed models were fit to assess whether the use of a volumetric report was associated with higher accuracy, accounting for random effects of within-rater and within-subject variability. Post hoc within-group analysis was performed with multiple comparisons correction. Residualized volumes were tested for an association with the diagnosis using ANOVA.

RESULTS

There was no statistically significant effect of the report on overall correct diagnoses. The proportion of "exact" correct diagnoses was higher with the report versus without the report for AD (0.52 versus 0.38) and FTD (0.49 versus 0.32) and lower for cognitively healthy (0.75 versus 0.89). The proportion of "rough" correct diagnoses of neurodegenerative disease was higher with the report than without the report within the AD group (0.59 versus 0.41), and it was similar within the FTD group (0.66 versus 0.63). Post hoc within-group analysis suggested that the report increased the accuracy in AD (OR = 2.77) and decreased the accuracy in cognitively healthy (OR = 0.25). Residualized hippocampal volumes were smaller in AD (mean difference -1.8; multiple comparisons correction, -2.8 to -0.8; P < .001) and FTD (mean difference -1.2; multiple comparisons correction, -2.2 to -0.1; P = .02) compared with cognitively healthy.

CONCLUSIONS

The availability of a brain volumetric report did not improve neuroradiologists' accuracy over visual assessment in diagnosing AD or FTD in this limited sample. Post hoc analysis suggested that the report may have biased readers incorrectly toward a diagnosis of neurodegeneration in cognitively healthy adults.

Trends in Memory Function and Memory Impairment Among Older Adults in the United States and Europe, 1996-2018

BACKGROUND

Single-country studies document varying time trends in memory function and impairment. Comparative analyses are limited.

METHODS

We used self-respondent data on adults aged 50+ years in 13 countries from 3 surveys (United States: Health and Retirement Study, 1998-2018; England: English Longitudinal Study of Ageing, 2002-2018; 11 European countries: Survey of Health, Ageing and Retirement in Europe, 2004-2019). Memory is measured with tests of immediate and delayed word recall. Unweighted age- and gender-adjusted mixed effects regression models as well as models with adjustments for additional sociodemographic characteristics and health behaviors were examined. Heterogeneity in trends by gender, age group, and educational attainment was measured.

RESULTS

The age-adjusted 10-year improvement in average test score is 0.04 standard deviations (SDs) (95% confidence interval [CI]: 0.03, 0.05) in the United States, 0.17 SDs (95% CI: 0.15, 0.19) in England, and 0.24 SDs (95% CI: 0.23, 0.25) in SHARE countries. Trends are largely similar across gender, age groups, and educational attainment. Regional differences in trends remain after adjustment for potential mechanisms. The difference between the United States and other countries is particularly large under 75 years of age compared to 75 years and older.

CONCLUSIONS

Pace of improvement in memory function varies strongly across countries. On average, the 11 European countries studied had the fastest improvement, followed by England. The trend in the United States indicates improvement, but at a much slower pace compared to that in England and other European countries. Uncovering the causes for the cross-country heterogeneity in time trends, and in particular the reasons for the comparatively poor performance of the United States, should be both a research and public health priority.

The effects of different types of exercises on cognition in older persons with mild cognitive impairment: A systematic review and meta-analysis

PURPOSE

This systematic review with meta-analysis aims to analyze the effects of different types of exercise on cognition, neuroprotective and neuroinflammatory blood markers in older adults with mild cognitive impairment (MCI).

METHODS

Relevant studies were identified using PubMED, SPORTDiscuss, Web of Science, Scopus, and PsycInfo databases. Methodological quality assessment of the studies was done with modified Downs and Black checklist. Data obtained from the included studies was analyzed using Comprehensive Meta-Analysis 4.0 software and results were reported using the random effects method.

RESULTS

A total of twenty-three studies were identified. The findings were summarized as change in cognitive function after the exercise interventions in general and after each type of exercise. On average, the exercise intervention revealed an effect size (ES): 1.165; 0.741 to 1.589 (95% Confidence Interval (CI); p < 0.001); aerobic exercise ES: 1.442; 0.624 to 2.260 (95 %CI); p = 0.001; Multimodal ES: 0,856; 0.366 to 1.346 (95 % CI); p = 0.001 and resistance exercise ES: 1.229; 0.339 to 2.120 (95 % CI); p = 0.007. In addition, we observed significant small ES: -0.475; -0.817 to -0.134 (95 %CI); p = 0.006, I2= 0 %; τ2 = 0 of exercise effects on Tumor Necrosis Factor-α (TNF-α) and non-significant large ES:0.952; -0.238 to 2.142 (95 %CI); p = 0.117 on Brain Derived Neurotrophic Factor (BDNF) in persons with MCI.

CONCLUSION

The present study revealed the existence of a large positive effect of overall exercise intervention on cognitive function and a small effect on TNF-α in old people with MCI. Additionally, this study demonstrates that aerobic and resistance exercises had similar larger positive effects and were better than multimodal exercise on increasing cognition in older persons with MCI.

The Impact of Lexical-semantic Impairment on Spoken Verb Production in Individuals With Mild Cognitive Impairment

BACKGROUND

Although episodic memory is the primary concern in individuals with mild cognitive impairment (MCI), other cognitive functions may also be affected, including language. Language impairment in individuals with MCI has been attributed primarily to the breakdown of semantic representations, difficulties in accessing semantic information, and the weakening of executive functions. However, in most prior studies of word processing in individuals with MCI, researchers have used measures focused on noun production.

OBJECTIVE

To investigate how verb production tasks might aid in detecting cognitive impairment in individuals with MCI.

METHODS

We compared the performance of 45 individuals with MCI and 45 healthy controls on action naming and action fluency tasks.

RESULTS

In the action naming task, the performance of participants with MCI was significantly impaired compared to healthy controls in terms of total score, the number of semantic errors produced, and the use of generic terms. In the action fluency task, participants with MCI produced significantly fewer verbs, fewer clusters, and fewer switches than healthy controls.

CONCLUSION

The results of our study emphasize the utility of verb production tasks in the identification of cognitive impairment in individuals with MCI and provide evidence of the importance of including action naming and action fluency tasks in the assessment of individuals with MCI.

Abnormal postcentral gyrus voxel-mirrored homotopic connectivity as a biomarker of mild cognitive impairment: A resting-state fMRI and support vector machine analysis

BACKGROUND

While patients affected by mild cognitive impairment (MCI) exhibit characteristic voxel-mirrored homotopic connectivity (VMHC) alterations, the ability of such VMHC abnormalities to predict the diagnosis of MCI in these patients remains uncertain. As such, this study was performed to evaluate the potential role of VMHC abnormalities in the diagnosis of MCI.

METHODS

MCI patients and healthy controls (HCs) were enrolled and subjected to resting-state functional magnetic resonance imaging (rs-fMRI) and neuropsychological testing. VMHC and support vector machine (SVM) techniques were then used to examine the collected imaging data.

RESULTS

Totally, 53 MCI patients and 68 healthy controls were recruited. Compared to HCs, MCI patients presented with an increase in postcentral gyrus VMHC. SVM classification demonstrated the ability of postcentral gyrus VMHC values to classify HCs and MCI patients with accuracy, sensitivity, and specificity values of 63.64 %, 71.69 %, and 89.71 %, respectively.

CONCLUSION

VMHC abnormalities in the postcentral gyrus may be mechanistically involved in the pathophysiological progression of MCI patients, and these abnormal VMHC patterns may also offer utility as a neuroimaging biomarker for MCI patient diagnosis.

Elucidating the Link Between Anxiety/Depression and Alzheimer's Dementia in the Australian Imaging Biomarkers and Lifestyle (AIBL) Study

BACKGROUND

The associations between mood disorders (anxiety and depression) and mild cognitive impairment (MCI) or Alzheimer's dementia (AD) remain unclear.

METHODS

Data from the Australian Imaging, Biomarker & Lifestyle (AIBL) study were subjected to logistic regression to determine both cross-sectional and longitudinal associations between anxiety/depression and MCI/AD. Effect modification by selected covariates was analysed using the likelihood ratio test.

RESULTS

Cross-sectional analysis was performed to explore the association between anxiety/depression and MCI/AD among 2,209 participants with a mean [SD] age of 72.3 [7.4] years, of whom 55.4% were female. After adjusting for confounding variables, we found a significant increase in the odds of AD among participants with two mood disorders (anxiety: OR 1.65 [95% CI 1.04-2.60]; depression: OR 1.73 [1.12-2.69]). Longitudinal analysis was conducted to explore the target associations among 1,379 participants with a mean age of 71.2 [6.6] years, of whom 56.3% were female. During a mean follow-up of 5.0 [4.2] years, 163 participants who developed MCI/AD (refer to as PRO) were identified. Only anxiety was associated with higher odds of PRO after adjusting for covariates (OR 1.56 [1.03-2.39]). However, after additional adjustment for depression, the association became insignificant. Additionally, age, sex, and marital status were identified as effect modifiers for the target associations.

CONCLUSION

Our study provides supportive evidence that anxiety and depression impact on the evolution of MCI/AD, which provides valuable epidemiological insights that can inform clinical practice, guiding clinicians in offering targeted dementia prevention and surveillance programs to the at-risk populations.

Real-life management of patients with mild cognitive impairment: an Italian survey

BACKGROUND

Mild cognitive impairment (MCI) is a syndrome with heterogeneous underlying causes and different rates of disease progression, whose clinical heterogeneity leads to a wide variation in diagnostic and therapeutic approaches in clinical practice. The lack of uniform practical recommendations on diagnostic workup and treatment for MCI patients hinders optimal management of these patients, worsening their prognosis. Standardized guidelines for the investigation and follow-up of MCI are therefore urgently required.

AIM

Aim of our study was to assess the diagnostic and therapeutic approach to MCI patients in the setting of Italian Memory Clinics.

METHODS

A survey was delivered to a sample of Italian neurologists through two different phases: a first exploratory phase recording general information about the usual clinical management of patients with MCI, and a subsequent operative phase assessing the practical diagnostic and therapeutic decisions taken in a real life setting to manage subjects with MCI.

RESULTS

A total of 121 neurologists participated to the first phase of the survey and 203 patients were enrolled in the second phase. Information gathered in the first phase of the survey highlighted a non-uniform use of diagnostic criteria and procedures for MCI, as well as a very heterogeneous therapeutic strategy among Italian neurologists. In the second phase, recorded data on diagnostic and therapeutic approach confirmed the large variability observed in the first phase of the survey.

CONCLUSIONS

The results of our study reflect a suboptimal management of MCI patients in Italy and highlight the need of standardized diagnostic and therapeutic approaches for this condition.

Frontiers and hotspots evolution in mild cognitive impairment: a bibliometric analysis of from 2013 to 2023

Background

Mild cognitive impairment is a heterogeneous syndrome. The heterogeneity of the syndrome and the absence of consensus limited the advancement of MCI. The purpose of our research is to create a visual framework of the last decade, highlight the hotspots of current research, and forecast the most fruitful avenues for future MCI research.

Methods

We collected all the MCI-related literature published between 1 January 2013, and 24 April 2023, on the "Web of Science." The visual graph was created by the CiteSpace and VOSviewer. The current research hotspots and future research directions are summarized through the analysis of keywords and co-cited literature.

Results

There are 6,075 articles were included in the final analysis. The number of publications shows an upward trend, especially after 2018. The United States and the University of California System are the most prolific countries and institutions, respectively. Petersen is the author who ranks first in terms of publication volume and influence. Journal of Alzheimer's Disease was the most productive journal. "neuroimaging," "fluid markers," and "predictors" are the focus of current research, and "machine learning," "electroencephalogram," "deep learning," and "blood biomarkers" are potential research directions in the future.

Conclusion

The cognition of MCI has been continuously evolved and renewed by multiple countries' joint efforts in the past decade. Hotspots for current research are on diagnostic biomarkers, such as fluid markers, neuroimaging, and so on. Future hotspots might be focused on the best prognostic and diagnostic models generated by machine learning and large-scale screening tools such as EEG and blood biomarkers.

Management of MCI in the Outpatient Setting

PURPOSE OF REVIEW

We review current literature related to the clinical assessment of Mild Cognitive Impairment (MCI). We compile recommendations related to the evaluation of MCI and examine literature regarding the use of clinical biomarkers in this assessment, the role of non-pharmacologic therapy in the prevention of cognitive decline, and recent approval of anti-amyloid therapy in the treatment of MCI.

RECENT FINDINGS

The role of imaging and plasma biomarkers in the clinical assessment of MCI has expanded. There is data that non-pharmacologic therapy may have a role in the prevention of neurocognitive decline. Anti-amyloid therapies have recently been approved for clinical use. Clinical assessment of MCI remains multifactorial and includes screening and treating for underlying psychiatric and medical co-morbidities. The use of biomarkers in clinical settings is expanding with the rise of anti-amyloid therapies. These new diagnostics and therapeutics require nuanced discussion of risks and benefits. Psychiatrist's skillset is uniquely suited for these complex evaluations.

Outcomes of Patients With Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease at 3 and 5 Years After Diagnosis

BACKGROUND AND OBJECTIVES

Retrospective studies indicate that dementia with Lewy bodies (DLB) may be preceded by a mild cognitive impairment (MCI) prodrome. Research criteria for the prospective identification of MCI with Lewy bodies (MCI-LB) have been developed. We aimed to assess the prognosis of a prospectively identified MCI-LB cohort at 2 key milestones, 3- and 5 years after diagnosis, to examine classification stability over time and rates of adverse outcomes (dementia or death).

METHODS

This was a retrospective examination of data from 2 longitudinal observational cohort studies where participants with MCI were prospectively recruited from North East England and differentially classified as MCI due to Alzheimer disease (MCI-AD), possible MCI-LB, or probable MCI-LB. Adverse outcomes (DLB/other dementia or death) and stability of disease-specific classifications were examined in each group.

RESULTS

Of 152 participants with baseline MCI (54 MCI-AD, 29 possible MCI-LB, and 69 probable MCI-LB), 126 were followed for up to 3 years (mean age 75.3 years; 40% female). We found that prospective probable MCI-LB classifications were both sensitive (91%) and specific (94%) to classifications either remaining as probable MCI-LB or progressing to DLB (in some cases autopsy confirmed) for 3 or more years after. Classifications were at least as stable as those in MCI-AD. In this cohort with disease-specific MCI classifications, rates of progression to dementia were high: 55% of MCI-LB had developed DLB within 3 years. Dementia occurred in 47% of MCI-AD over the same duration (odds ratio 1.68, 95% CI 0.66-4.26, p = 0.278). Premature death was a common competing risk, occurring in 9% of MCI-AD and 11% of MCI-LB within 3 years.

DISCUSSION

These findings support that prospectively identified probable MCI-LB is a prodromal presentation of DLB and that disease-specific classifications of MCI may reliably identify different prodromal dementias.

Patterns of cognitive domain abnormalities enhance discrimination of dementia risk prediction: The ARIC study

INTRODUCTION

The contribution of neuropsychological assessments to risk assessment for incident dementia is underappreciated.

METHODS

We analyzed neuropsychological testing results in dementia-free participants in the Atherosclerosis Risk in Communities (ARIC) study. We examined associations of index domain-specific neuropsychological test performance with incident dementia using cumulative incidence curves and Cox proportional hazards models.

RESULTS

Among 5296 initially dementia-free participants (mean [standard deviation] age of 75.8 [5.1] years; 60.1% women, 22.2% Black) over a median follow-up of 7.9 years, the covariate-adjusted hazard ratio varied substantially depending on the pattern of domain-specific performance and age, in an orderly manner from single domain language abnormalities (lowest risk) to single domain executive or memory abnormalities, to multidomain abnormalities including memory (highest risk).

DISCUSSION

By identifying normatively defined cognitive abnormalities by domains based on neuropsychological test performance, there is a conceptually orderly and age-sensitive spectrum of risk for incident dementia that provides valuable information about the likelihood of progression.

HIGHLIGHTS

Domain-specific cognitive profiles carry enhanced prognostic value compared to mild cognitive impairment. Single-domain non-amnestic cognitive abnormalities have the most favorable prognosis. Multidomain amnestic abnormalities have the greatest risk for incident dementia. Patterns of domain-specific risks are similar by sex and race.

Neural markers of reduced arousal and consciousness in mild cognitive impairment

OBJECTIVES

People with Alzheimer's Disease (AD) experience changes in their level and content of consciousness, but there is little research on biomarkers of consciousness in pre-clinical AD and Mild Cognitive Impairment (MCI). This study investigated whether levels of consciousness are decreased in people with MCI.

METHODS

A multi-site site magnetoencephalography (MEG) dataset, BIOFIND, comprising 83 people with MCI and 83 age matched controls, was analysed. Arousal (and drowsiness) was assessed by computing the theta-alpha ratio (TAR). The Lempel-Ziv algorithm (LZ) was used to quantify the information content of brain activity, with higher LZ values indicating greater complexity and potentially a higher level of consciousness.

RESULTS

LZ was lower in the MCI group versus controls, indicating a reduced level of consciousness in MCI. TAR was higher in the MCI group versus controls, indicating a reduced level of arousal (i.e. increased drowsiness) in MCI. LZ was also found to be correlated with mini-mental state examination (MMSE) scores, suggesting an association between cognitive impairment and level of consciousness in people with MCI.

CONCLUSIONS

A decline in consciousness and arousal can be seen in MCI. As cognitive impairment worsens, measured by MMSE scores, levels of consciousness and arousal decrease. These findings highlight how monitoring consciousness using biomarkers could help understand and manage impairments found at the preclinical stages of AD. Further research is needed to explore markers of consciousness between people who progress from MCI to dementia and those who do not, and in people with moderate and severe AD, to promote person-centred care.

Wearable Sensors in Other Medical Domains with Application Potential for Orthopedic Trauma Surgery-A Narrative Review

The use of wearable technology is steadily increasing. In orthopedic trauma surgery, where the musculoskeletal system is directly affected, focus has been directed towards assessing aspects of physical functioning, activity behavior, and mobility/disability. This includes sensors and algorithms to monitor real-world walking speed, daily step counts, ground reaction forces, or range of motion. Several specific reviews have focused on this domain. In other medical fields, wearable sensors and algorithms to monitor digital biometrics have been used with a focus on domain-specific health aspects such as heart rate, sleep, blood oxygen saturation, or fall risk. This review explores the most common clinical and research use cases of wearable sensors in other medical domains and, from it, derives suggestions for the meaningful transfer and application in an orthopedic trauma context.

The Cerebrospinal Fluid Free-Glycans Hex1 and HexNAc1Hex1Neu5Ac1 as Potential Biomarkers of Alzheimer's Disease

Alzheimer's disease (AD) is the most common neurodegenerative disorder, affecting a growing number of elderly people. In order to improve the early and differential diagnosis of AD, better biomarkers are needed. Glycosylation is a protein post-translational modification that is modulated in the course of many diseases, including neurodegeneration. Aiming to improve AD diagnosis and differential diagnosis through glycan analytics methods, we report the glycoprotein glycome of cerebrospinal fluid (CSF) isolated from a total study cohort of 262 subjects. The study cohort consisted of patients with AD, healthy controls and patients suffering from other types of dementia. CSF free-glycans were also isolated and analyzed in this study, and the results reported for the first time the presence of 19 free glycans in this body fluid. The free-glycans consisted of complete or truncated N-/O-glycans as well as free monosaccharides. The free-glycans Hex1 and HexNAc1Hex1Neu5Ac1 were able to discriminate AD from controls and from patients suffering from other types of dementia. Regarding CSF N-glycosylation, high proportions of high-mannose, biantennary bisecting core-fucosylated N-glycans were found, whereby only about 20% of the N-glycans were sialylated. O-Glycans and free-glycan fragments were less sialylated in AD patients than in controls. To conclude, this comprehensive study revealed for the first time the biomarker potential of free glycans for the differential diagnosis of AD.

A qualitative study of informal caregiver perceptions of the benefits of an early dementia diagnosis

BACKGROUND

Current and former dementia policies in the United Kingdom (UK) recommend diagnosing dementia early, or as close to the onset of symptoms as possible. Informal caregivers play an important role in initiating the diagnostic process and providing support to people living with dementia. Therefore, this study aimed to explore caregiver perceptions of the benefits of an early diagnosis.

METHODS

We conducted semi-structured interviews with 12 current and former informal caregivers to people with dementia in the UK in 2020. We analysed the interviews using thematic analysis.

RESULTS

Benefits of an early diagnosis included: (1) protecting the person with dementia from financial or physical harm, (2) timely decision-making, and (3) access to services and treatments following a diagnosis. We identified three conditions necessary for the benefits of an early diagnosis to be felt: (1) adequate prognostic information, (2) someone to advocate on behalf of the person with dementia, and (3) a willingness to seek and accept the diagnosis.

CONCLUSIONS

In this study, we identified how diagnosing dementia close to the onset of symptoms could be beneficial and the conditions necessary for these benefits to be felt. The findings highlight the importance of an early diagnosis for enabling people with dementia and caregivers to make practical arrangements and to access services. Further research is needed to build on the findings of this study by exploring the perspectives of people with dementia and by including a larger, more diverse sample of caregivers.

A network approach to subjective cognitive decline: Exploring multivariate relationships in neuropsychological test performance across Alzheimer's disease risk states

Subjective cognitive decline (SCD) is characterized by subjective concerns of cognitive change despite test performance within normal range. Although those with SCD are at higher risk for developing further cognitive decline, we still lack methods using objective cognitive measures that reliably distinguish SCD from cognitively normal aging at the group level. Network analysis may help to address this by modeling cognitive performance as a web of intertwined cognitive abilities, providing insight into the multivariate associations determining cognitive status. Following previous network studies of mild cognitive impairment (MCI) and Alzheimer's dementia (AD), the current study centered upon the novel visualization and analysis of the SCD cognitive network compared to cognitively normal (CN) older adult, MCI, and AD group networks. Cross-sectional neuropsychological data from CIMA-Q and COMPASS-ND cohorts were used to construct Gaussian graphical models for CN (n = 122), SCD (n = 207), MCI (n = 210), and AD (n = 79) groups. Group networks were explored in terms of global network structure, prominent edge weights, and strength centrality indices. CN and SCD group networks were contrasted using the Network Comparison Test. Results indicate that CN and SCD groups did not differ in univariate cognitive performance or global network structure. However, measures of strength centrality, principally in executive functioning and processing speed, showed a CN-SCD-MCI gradient where subtle differences within the SCD network suggest that SCD is an intermediary between CN and MCI stages. Additional results may indicate a distinctiveness of network structure in AD, a reversal in network influence between age and general cognitive status as clinical impairment increases, and potential evidence for cognitive reserve. Together, these results provide evidence that network-specific metrics are sensitive to cognitive performance changes across the dementia risk spectrum and can help to objectively distinguish SCD group cognitive performance from that of the CN group.

Prevalence and risk factors of mild cognitive impairment in a tertiary care setting in Turkey

BACKGROUND

Mild cognitive impairment (MCI) is an intermediate stage between healthy cognition and dementia, particularly Alzheimer's disease. There is limited information on the prevalence of MCI among older Turkish adults. This study aimed to determine the prevalence and risk factors of MCI in Turkey.

MATERIAL AND METHODS

A cross-sectional study was conducted with community-dwelling older people who were admitted to a tertiary geriatric outpatient clinic. Information on demographics and clinical variables was obtained. We used a neuropsychological battery to assess the cognitive domains in each subject. Participants who fell below 1.5 standard deviations on 1 or more of the 5 cognitive tests were considered MCI and were classified as either single domain MCI and multiple domain MCI. Risk factors were determined using univariate and multivariate logistic regression analyses.

RESULTS

A total of 259 participants were enrolled in this study. The mean age was 74.0 years (SD 7.1 years), 54% were women, and 48.3% had a low level of education (≤ 5 years). The overall prevalence of MCI was 52.1%, with 27.8% for single domain MCI and 24.3% for multiple domain MCI. The prevalence of MCI increased with age: 16.4% aged 65-74 years, 32.0% aged 75-84 years, and 40.9% ≥ 85 years. Advanced age and low educational level were risk factors for both single domain MCI (OR = 1.07; 95% CI: 1.02-1.13; p = 0.003 and OR = 3.18; 95% CI:1.7-6.1; p < 0.001) and multiple domain MCI (OR = 1.1; 95% CI:1.1-1.2; p < 0.001 and adjusted OR = 11.9; 95% CI:5.1-27.8; p < 0.001).

CONCLUSION

MCI was common in older Turkish people admitted to a tertiary hospital, especially in those with advanced age and low educational level.

New horizons in the diagnosis and management of Alzheimer's Disease in older adults

Alzheimer's Disease (ad) is the most common cause of dementia, and in addition to cognitive decline, it directly contributes to physical frailty, falls, incontinence, institutionalisation and polypharmacy in older adults. Increasing availability of clinically validated biomarkers including cerebrospinal fluid and positron emission tomography to assess both amyloid and tau pathology has led to a reconceptualisation of ad as a clinical-biological diagnosis, rather than one based purely on clinical phenotype. However, co-pathology is frequent in older adults which influence the accuracy of biomarker interpretation. Importantly, some older adults with positive amyloid or tau pathological biomarkers may never experience cognitive impairment or dementia. These strides towards achieving an accurate clinical-biological diagnosis are occurring alongside recent positive phase 3 trial results reporting statistically significant effects of anti-amyloid Disease-Modifying Therapies (DMTs) on disease severity in early ad. However, the real-world clinical benefit of these DMTs is not clear and concerns remain regarding how trial results will translate to real-world clinical populations, potential adverse effects (including amyloid-related imaging abnormalities), which can be severe and healthcare systems readiness to afford and deliver potential DMTs to appropriate populations. Here, we review recent advances in both clinical-biological diagnostic classification and future treatment in older adults living with ad. Advocating for access to both more accurate clinical-biological diagnosis and potential DMTs must be done so in a holistic and gerontologically attuned fashion, with geriatricians advocating for enhanced multi-component and multi-disciplinary care for all older adults with ad. This includes those across the ad severity spectrum including older adults potentially ineligible for emerging DMTs.

Monoclonal antibodies for treating early Alzheimer disease-a commentary on recent 'positive' trials

Recent phase 3 randomised controlled trials of amyloid-targeting monoclonal antibodies in people with pre-clinical or early Alzheimer disease have reported positive results, raising hope of finally having disease-modifying drugs. Given their far-reaching implications for clinical practice, the methods and findings of these trials, and the disease causation theory underpinning the mechanism of drug action, need to be critically appraised. Key considerations are the representativeness of trial populations; balance of prognostic factors at baseline; psychometric properties and minimal clinically important differences of the primary efficacy outcome measures; level of study fidelity; consistency of subgroup analyses; replication of findings in similar trials; sponsor role and potential conflicts of interest; consistency of results with disease causation theory; cost and resource estimates; and alternative prevention and treatment strategies. In this commentary, we show shortcomings in each of these areas and conclude that monoclonal antibody treatment for early Alzheimer disease is lacking high-quality evidence of clinically meaningful impacts at an affordable cost.

Prevalence, cognitive characteristics, and influencing factors of amnestic mild cognitive impairment among older adults residing in an urban community in Chengdu, China

Objective

Dementia is a significant public health concern, and mild cognitive impairment (MCI) serves as a transitional stage between normal aging and dementia. Among the various types of MCI, amnestic MCI (aMCI) has been identified as having a higher likelihood of progressing to Alzheimer's dimension. However, limited research has been conducted on the prevalence of aMCI in China. Therefore, the objective of this study is to investigate the prevalence of aMCI, examine its cognitive characteristics, and identify associated risk factors.

Methods

In this cross-sectional study, we investigated a sample of 368 older adults aged 60 years and above in the urban communities of Chengdu, China. The participants underwent a battery of neuropsychological assessments, including the Mini-Mental State Examination (MMSE), the Clinical Dementia Rating (CDR), Auditory Verbal Learning Test (AVLT), Wechsler's Logical Memory Task (LMT), Boston Naming Test (BNT) and Trail Making Test Part A (TMT-A). Social information was collected by standard questionnaire. Multiple logistic regression analysis was utilized to screen for the risk and protective factors of aMCI.

Results

The data analysis included 309 subjects with normal cognitive function and 59 with aMCI, resulting in a prevalence of 16.0% for aMCI. The average age of participants was 69.06 ± 7.30 years, with 56.0% being females. After controlling for age, gender and education, the Spearman partial correlation coefficient between various cognitive assessments and aMCI ranged from -0.52 for the long-term delayed recall scores in AVLT to 0.19 for the time-usage scores in TMT-A. The results indicated that all cognitive domains, except for naming scores (after semantic cue of BNT) and error quantity (in TMT-A), showed statistically significant associations with aMCI. Furthermore, the multiple logistic regression analysis revealed that older age (OR = 1.044, 95%CI: 1.002~1.087), lower educational level, and diabetes (OR = 2.450, 95%CI: 1.246~4.818) were risk factors of aMCI.

Conclusion

This study found a high prevalence of aMCI among older adults in Chengdu, China. Individuals with aMCI exhibited lower cognitive function in memory, language, and executive domains, with long-term delayed recall showing the strongest association. Clinicians should prioritize individuals with verbal learning and memory difficulties, especially long-term delayed recall, in clinical practice.

Dementia care pathways in prisons - a comprehensive scoping review

BACKGROUND

The number of older people in prison is growing. As a result, there will also be more prisoners suffering from dementia. The support and management of this population is likely to present multiple challenges to the prison system.

OBJECTIVES

To examine the published literature on the care and supervision of people living in prison with dementia and on transitioning into the community; to identify good practice and recommendations that might inform the development of prison dementia care pathways.

METHODS

A scoping review methodology was adopted with reporting guided by the PRISMA extension for scoping reviews checklist and explanation.

RESULTS

Sixty-seven papers were included. Most of these were from high income countries, with the majority from the United Kingdom (n = 34), followed by the United States (n = 15), and Australia (n = 12). One further paper was from India.

DISCUSSION

The literature indicated that there were difficulties across the prison system for people with dementia along the pathway from reception to release and resettlement. These touched upon all aspects of prison life and its environment, including health and social care. A lack of resources and national and regional policies were identified as important barriers, although a number of solutions were also identified in the literature, including the development of locally tailored policies and increased collaboration with the voluntary sector.

CONCLUSION

To our knowledge, this is the most comprehensive and inclusive review of the literature on dementia care pathways in prison to date. It has identified a number of important areas of concern and opportunities for future research across the prison system, and its operations. This will hopefully lead to the identification or adaptation of interventions to be implemented and evaluated, and facilitate the development of dementia care pathways in prisons.

APOE ε4 positivity predicts centrality of episodic memory nodes in patients with mild cognitive impairment: A cohort-based, graph theory-informed study of cognitive networks

As network neuroscience can capture the systemic impact of APOE variability at a neuroimaging level, this study investigated the network-based cognitive endophenotypes of ε4-carriers and non-carriers across the continuum between normal ageing and Alzheimer's dementia (AD). We hypothesised that the impact of APOE-ε4 on cognitive functioning can be reliably captured by the measurement of graph-theory centrality. Cognitive networks were calculated in 8118 controls, 3482 MCI patients and 4573 AD patients, recruited in the National Alzheimer's Coordinating Center (NACC) database. Nodal centrality was selected as the neurofunctional readout of interest. ε4-carrier-vs.-non-carrier differences were tested in two independent NACC sub-cohorts assessed with either Version 1 or Version 2 of the Uniform Data Set neuropsychological battery. A significant APOE-dependent effect emerged from the analysis of the Logical-Memory nodes in MCI patients in both sub-cohorts. While non-carriers showed equal centrality in immediate and delayed recall, the latter was significantly less central among carriers (v1: bootstrapped confidence interval 0.107-0.667, p < 0.001; v2: bootstrapped confidence interval 0.018-0.432, p < 0.001). This indicates that, in carriers, delayed recall was, overall, significantly more weakly correlated with the other cognitive scores. These findings were replicated in the sub-groups of sole amnestic-MCI patients (n = 2971), were independent of differences in network communities, clinical severity or other demographic factors. No effects were found in the other two diagnostic groups. APOE-ε4 influences nodal properties of cognitive networks when patients are clinically classified as MCI. This highlights the importance of characterising the impact of risk factors on the wider cognitive network via network-neuroscience methodologies.

What Impact Does the Diagnosis of Mild Cognitive Impairment Have on the Wellbeing, Everyday Behavior, and Healthcare Utilization of People and Their Carers? A Systematic Review

Background

Dementia is a major cause of disability and dependency globally. Mild cognitive impairment (MCI) is considered an early indicator of developing dementia. There are growing efforts to detect and diagnose MCI earlier; consequently, we need to understand the perspectives of individuals and carers regarding the implications of an MCI diagnosis.

Objective

To systematically review qualitative literature to understand the impact of a MCI diagnosis on both the individual and their carers, focusing on wellbeing, everyday behaviors, and healthcare utilization.

Methods

Key search terms were input into five databases. Studies were included if they were peer-reviewed qualitative research published in English that obtained perspectives of community-dwellers with MCI or carers and focused on either their wellbeing, everyday behaviors and/or healthcare utilization. The protocol was pre-registered on PROSPERO (CRD42021291995). Data was synthesized narratively.

Results

Key findings from 15 eligible articles highlighted the negative impact of an MCI diagnosis on the wellbeing of both individuals and carers, due to stigma and limited understanding regarding diagnosis/prognosis. Changes in everyday behavior varied, particularly regarding motivation to engage with physical activity, hobbies and social opportunities. Both individuals and carers were sometimes dissatisfied with healthcare services; ineffective communication during clinical consolations highlighted as a reason for lack of trust in clinicians.

Conclusions

Results indicate that an MCI diagnosis impacts both people with MCI and their carers across key facets of life. There is a critical need to effectively communicate the diagnosis and prognosis of MCI to support wellbeing and everyday activities and ensure trust in healthcare services.

[Immunological and neuroanatomic markers of the clinical dynamics of MCI and pre-MCI]

OBJECTIVE

To study the relationship of the parameters of immunity and systemic inflammation with the structural magnetic resonance imaging (MRI) parameters in patients with mild cognitive impairment (MCI) and pre-MCI undergoing neurocognitive rehabilitation to search for candidate markers of its effectiveness.

MATERIAL AND METHODS

The main group included 49 patients, aged ≥60 years, with MCI and pre-MCI with memory impairment, who underwent a course of neurorehabilitation for 5 weeks. The control group included 19 volunteers of similar age with a total MoCA score of ≥25, who did not have cognitive impairment and immuno-inflammatory disorders. The parameters of cellular and humoral immunity and markers of inflammation were studied, and structural MRI was performed.

RESULTS

The content of activated natural killer cells (NK-cells) was increased in MCI and pre-MCI (0.63±0.12% vs. 0.22±0.07% in the control group, p=2.2·10-7). The level of immunoglobulin G (IgG) <12.5 g/l in patients with MCI and pre-MCI with the Montreal Cognitive Assessment Scale (MoCA) score <22 was associated with a decrease in the volume of the right nucleus accumbens (376±35 mm3 in patients with IgG <12.5 g/l (p=0.0013) and 480±44 mm3 at IgG <12.5 g/l, 480±44 mm3 in the control group), as well as with a decrease of the thickness and volume of a number of other cortical zones. A logistic regression model including the level of immunoglobulin G, NK cells, CD8+ NK cells and right amygdala volume was constructed to predict the number of MoCA scores 6 months after the course of rehabilitation (R2=0.57; p<1·10-5; standard error of estimate: 2.93).

CONCLUSION

As a result of this work, the perspectives of assessing the immunological parameters in combination with socio-demographic data and morphometric changes of the brain as potential prognostic markers of the dynamics of cognitive impairment in patients with MCI and pre-MCI after neurorehabilitation has been shown.

Enlarged Perivascular Spaces Are Independently Associated with High Pulse Wave Velocity: A Cross-Sectional Study

Background

Recent studies have demonstrated an association between pulse wave velocity (PWV), cerebral small vessel disease (SVD), and cognitive impairment such as Alzheimer's disease. However, the association between brachial-ankle PWV and enlarged perivascular spaces (EPVS), one component of cerebral SVD remains controversial.

Objective

To investigate the relationship between brachial-ankle PWV and EPVS severity in participants without dementia.

Methods

We performed a cross-sectional study of data of 74 participants from sub-analysis of ongoing research. We assessed cognitive function, brachial-ankle PWV, and brain magnetic resonance imaging (MRI) features. Using brain MRI, EPVS were separately assessed as basal ganglia (BG)-EPVS or centrum semiovale (CSO)-EPVS on the basis of their location. The relationship between EPVS severity and brachial-ankle PWV was evaluated using multivariable ordinal logistic regression analyses.

Results

We analyzed 74 participants (women: 47%, mean age: 73 years, mild cognitive impairment [MCI]: 74%). Compared with participants with normal cognition, those with MCI were more likely to have both severe BG-EPVS and severe CSO-EPVS. In multivariable analyses, high brachial-ankle PWV and age were independently associated with BG-EPVS severity (odds ratio [95% confidence interval]: 1.19 [1.02-1.38], 1.09 [1.01-1.17], respectively), whereas only age was independently associated with CSO-EPVS severity. A causal mediation analysis under a counterfactual approach revealed a significant pure natural indirect effect of brachial-ankle PWV on MCI that was mediated by BG-EPVS (estimate: 1.04, 95% CI: 1.01-1.12, p = 0.006).

Conclusions

Brachial-ankle PWV was associated with BG-EPVS severity. High PWV may cause cerebrovascular pulsatility, which accelerates BG-EPVS and may worsen cognitive impairment.

Protocol for the Tallaght University Hospital Institute for Memory and Cognition-Biobank for Research in Ageing and Neurodegeneration

INTRODUCTION

Alzheimer's disease and other dementias affect >50 million individuals globally and are characterised by broad clinical and biological heterogeneity. Cohort and biobank studies have played a critical role in advancing the understanding of disease pathophysiology and in identifying novel diagnostic and treatment approaches. However, further discovery and validation cohorts are required to clarify the real-world utility of new biomarkers, facilitate research into the development of novel therapies and advance our understanding of the clinical heterogeneity and pathobiology of neurodegenerative diseases.

METHODS AND ANALYSIS

The Tallaght University Hospital Institute for Memory and Cognition Biobank for Research in Ageing and Neurodegeneration (TIMC-BRAiN) will recruit 1000 individuals over 5 years. Participants, who are undergoing diagnostic workup in the TIMC Memory Assessment and Support Service (TIMC-MASS), will opt to donate clinical data and biological samples to a biobank. All participants will complete a detailed clinical, neuropsychological and dementia severity assessment (including Addenbrooke's Cognitive Assessment, Repeatable Battery for Assessment of Neuropsychological Status, Clinical Dementia Rating Scale). Participants undergoing venepuncture/lumbar puncture as part of the clinical workup will be offered the opportunity to donate additional blood (serum/plasma/whole blood) and cerebrospinal fluid samples for longitudinal storage in the TIMC-BRAiN biobank. Participants are followed at 18-month intervals for repeat clinical and cognitive assessments. Anonymised clinical data and biological samples will be stored securely in a central repository and used to facilitate future studies concerned with advancing the diagnosis and treatment of neurodegenerative diseases.

ETHICS AND DISSEMINATION

Ethical approval has been granted by the St. James's Hospital/Tallaght University Hospital Joint Research Ethics Committee (Project ID: 2159), which operates in compliance with the European Communities (Clinical Trials on Medicinal Products for Human Use) Regulations 2004 and ICH Good Clinical Practice Guidelines. Findings using TIMC-BRAiN will be published in a timely and open-access fashion.

Correlation between the Cognitive Status (SIRT1) and the Metabolic Function in Geriatric Patients Using the Indonesian Version of the Montreal Cognitive Assessment (MoCA-INA)

A growing life expectancy may result in a chronic medical condition and multimorbidity because the aging process leads to a decrease in cognitive and physiological function. These risks may affect the quality of life of geriatrics. The present study aims to determine the correlation between cognitive status (in terms of SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent class III deacetylase) and metabolic function (in terms of the lipid profile, kidney function, and blood glucose) in geriatric patients. The differences in the parameters of metabolic function in the participants' cognitive status were determined by using the Indonesian version of the Montreal Cognitive Assessments (MoCA-Ina). The elderly participants (n = 120) were recruited at three sites in Indonesia from March to October 2022. Our study demonstrated a negative correlation between the cognitive status of geriatric patients and their metabolic function, represented by the MoCA-Ina score with a linear regression equation of y = 0.27 - 2.4 ×10-3x. Higher levels of LDL-C, cystatin C, and HbA1c were found in the Severe-Moderate Cognitive Impairment group. Determining the SIRT1 levels may be beneficial in predicting both the cognitive and metabolic status of geriatrics because this protein is among numerous metabolic sensors in the hypothalamus.

Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review

INTRODUCTION

Artificial intelligence (AI) and neuroimaging offer new opportunities for diagnosis and prognosis of dementia.

METHODS

We systematically reviewed studies reporting AI for neuroimaging in diagnosis and/or prognosis of cognitive neurodegenerative diseases.

RESULTS

A total of 255 studies were identified. Most studies relied on the Alzheimer's Disease Neuroimaging Initiative dataset. Algorithmic classifiers were the most commonly used AI method (48%) and discriminative models performed best for differentiating Alzheimer's disease from controls. The accuracy of algorithms varied with the patient cohort, imaging modalities, and stratifiers used. Few studies performed validation in an independent cohort.

DISCUSSION

The literature has several methodological limitations including lack of sufficient algorithm development descriptions and standard definitions. We make recommendations to improve model validation including addressing key clinical questions, providing sufficient description of AI methods and validating findings in independent datasets. Collaborative approaches between experts in AI and medicine will help achieve the promising potential of AI tools in practice.

HIGHLIGHTS

There has been a rapid expansion in the use of machine learning for diagnosis and prognosis in neurodegenerative disease Most studies (71%) relied on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset with no other individual dataset used more than five times There has been a recent rise in the use of more complex discriminative models (e.g., neural networks) that performed better than other classifiers for classification of AD vs healthy controls We make recommendations to address methodological considerations, addressing key clinical questions, and validation We also make recommendations for the field more broadly to standardize outcome measures, address gaps in the literature, and monitor sources of bias.

Synergistic effect of Tai Chi and transcranial direct current stimulation on memory function in patients with mild cognitive impairment: study protocol for a 2×2 factorial randomised controlled trial

INTRODUCTION

Interventions at the mild cognitive impairment (MCI) stage prevent or delay the progression of cognitive decline. In recent years, several studies have shown that physical exercise combined with transcranial direct current stimulation (tDCS) effectively delays the disease and promotes cognitive recovery in patients with MCI. This study aims to determine whether Tai Chi (TC) combined with tDCS can significantly improve memory in patients with MCI compared with TC or tDCS alone.

METHODS AND ANALYSIS

This clinical trial will use a 2×2 factorial design, enrolling 128 community-dwelling MCI patients, randomly categorised into four groups: TC, tDCS, TC combined with tDCS and the health education group. Outcome measures will include the Chinese Wechsler Memory Scale-Revised, Auditory Verbal Learning Test and Rey-Osterrieth Complex Figure Test. All assessments will be conducted at baseline and 3 months after the intervention. All analyses will use intention-to-treat or per-protocol methods.

ETHICS AND DISSEMINATION

Ethics approval was obtained from the Ethics Committee of the Affiliated Rehabilitation Hospital of the Fujian University of Traditional Chinese Medicine (2022KY-002-01). The results of the study will be disseminated through peer-reviewed publications and at scientific conferences.

TRIAL REGISTRATION NUMBER

ChiCTR2200059316.

Plasma Aβ42:Aβ40 ratio as a biomarker for cognitive impairment in haemodialysis patients: a multicentre study

Background

Mild cognitive impairment (MCI) and dementia are more prevalent in patients undergoing haemodialysis (HD). Although the cerebrospinal fluid amyloid beta (Aβ) and tau (τ) have proven to be valid biomarkers for the diagnosis of Alzheimer's disease (AD) in the general population, the roles of plasma Aβ and τ for the diagnosis of cognitive impairment in HD patients remain unknown.

Methods

We conducted a cross-sectional study including patients receiving HD in three hospitals in Shanghai. All patients completed the Montreal Cognitive Assessment-Basic (MoCA-B). To validate the effectiveness of the MoCA-B score for screening MCI, a subset group underwent neuropsychological batteries. Serum proteomes were compared in HD patients with normal cognitive function and dementia. Plasma Aβ42, Aβ40 and total τ were measured using a single molecule array.

Results

A total of 311 HD patients were enrolled (mean age 63 years, 55% male). The best cut-off score of MoCA-B for differentiating MCI and normal cognition was 24, with an area under the curve of 0.94. Serum proteomics revealed that neurodegenerative pathways related to AD were enriched in HD patients with dementia. The plasma Aβ42:Aβ40 ratio was significantly reduced in patients with MCI and dementia and was independently associated with cognitive function after adjusting for age, sex and education levels.

Conclusions

We validated the MoCA-B as an optimal cognitive function screening instrument for MCI in HD patients. The plasma Aβ42:Aβ40 ratio was a potential biomarker in distinguishing normal cognition, MCI and dementia in HD populations.

Functional Cognitive Disorder: Diagnosis, Treatment, and Differentiation from Secondary Causes of Cognitive Difficulties

Functional cognitive disorder is an increasingly common cause of referral to the memory clinic. As a substantial source of disability, clinicians involved in the management of patients with cognitive complaints need to familiarize themselves with this important differential diagnosis. Our approach focuses on the identification of positive features of internal inconsistency (historical and clinical clues alongside patterns of performance) instead of an exclusionary approach. Although effective treatments are desperately needed, promising therapies include metacognitive retraining and cognitive-behavioral therapy modalities. Future research should focus on a better understanding of disease trajectories and outcomes as well as the development of evidence-based interventions.